^
Association details:
| Biomarker: | EGFR G719S + EGFR L861Q |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR ) Mutations with the Classical Mutation Pattern
Excerpt:
Our study had the largest group of patients with complex EGFR mutations. After combining all 34 patients with complex EGFR mutations from the other studies and the present study, there was a total of 53 lung adenocarcinoma patients with complex EGFR mutations...Two patients with G719A plus S768I had different maximum responses to EGFR TKIs...A similar condition was also noted in two patients with G719S plus L861Q.
DOI:
10.1634/theoncologist.2008-0093
